Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia [15]

Leukemia

Volumn 21, Issue 9, 2007, Pages 2071-2072

  Shvidel, L ^a   Sigler, E ^a   Haran, M ^a   Klepfish, A ^a   Duek, A ^a   Berrebi, A ^a   Shtalrid, M ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; BUSULFAN; HYDROXYUREA;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GERIATRIC PATIENT; HUMAN; LETTER; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RELAPSE; RETREATMENT; SHORT COURSE THERAPY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTHEMIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 34548125318     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404743     Document Type: Letter

References (8)

1. Tefferi A. Essential thrombopcythemia: Scientific advances and current practice. Curr Opin Hematol 2006; 13: 93-98.
2. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C et al. Acute leukemia in polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study. Blood 2005; 105 2664-2670.
3. Berrebi A, Shvidel L, Shtalrid M, Klepfish A. Short course of busulphan in essential thrombocythaemia: Remodelling of an old strategy. Br J Haematol 2000; 109: 249-250.
4. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29-39.
5. Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion. Blood 1998; 91: 616-622.
6. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al., UK MRC Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33-45.
7. Brodsky I. Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET). Am J Clin Oncol 1998; 21: 105-106.
8. Van de Pette JE, Prochazka AV, Pearson TC, Singh AK, Dickson ER, Wetherley-Mein G. Primary thrombocythaemia treated with busulphan. Br J Haematol 1986; 62: 229-237.